Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma.
Adaptor Proteins, Vesicular Transport
/ genetics
Adenosine Deaminase
/ metabolism
Age Factors
Alu Elements
Astrocytes
/ metabolism
Brain
/ metabolism
Brain Neoplasms
/ genetics
Case-Control Studies
Cell Line, Tumor
Glioblastoma
/ genetics
HEK293 Cells
Humans
Inosine
/ metabolism
RNA Editing
Sex Factors
ADAR
COG3
GBM
RNA editing
RNA-Seq
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
13 02 2019
13 02 2019
Historique:
received:
29
08
2018
accepted:
04
02
2019
entrez:
15
2
2019
pubmed:
15
2
2019
medline:
22
3
2019
Statut:
epublish
Résumé
Adenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by ADAR enzymes that have been recently associated with cancer. Here, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient groups for which more aggressive treatments may be necessary. Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.
Sections du résumé
BACKGROUND
Adenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by ADAR enzymes that have been recently associated with cancer.
RESULTS
Here, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient groups for which more aggressive treatments may be necessary.
CONCLUSIONS
Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future personalized targeted gene therapy.
Identifiants
pubmed: 30760294
doi: 10.1186/s13059-019-1647-x
pii: 10.1186/s13059-019-1647-x
pmc: PMC6373152
doi:
Substances chimiques
Adaptor Proteins, Vesicular Transport
0
COG3 protein, human
0
Inosine
5A614L51CT
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Références
RNA. 2000 May;6(5):755-67
pubmed: 10836796
Nature. 2000 Jul 6;406(6791):78-81
pubmed: 10894545
Science. 2000 Dec 1;290(5497):1765-8
pubmed: 11099415
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92
pubmed: 11717408
Drug Discov Today. 2003 Apr 1;8(7):307-15
pubmed: 12654543
PLoS Biol. 2004 Dec;2(12):e391
pubmed: 15534692
Genome Res. 2007 Nov;17(11):1586-95
pubmed: 17908822
J Biol Chem. 2008 Mar 14;283(11):7251-60
pubmed: 18178553
Nature. 2008 Mar 27;452(7186):473-7
pubmed: 18305480
Mol Pharmacol. 2009 Dec;76(6):1246-55
pubmed: 19783622
Cell. 1991 Jan 25;64(2):235-48
pubmed: 1988146
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Annu Rev Biochem. 2010;79:321-49
pubmed: 20192758
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
J Biol Chem. 2011 Mar 11;286(10):8325-37
pubmed: 21078670
PLoS One. 2012;7(2):e30619
pubmed: 22312429
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Nat Med. 2013 Feb;19(2):209-16
pubmed: 23291631
RNA Biol. 2013 Feb;10(2):321-33
pubmed: 23324600
Pflugers Arch. 2013 May;465(5):655-67
pubmed: 23397171
Bioinformatics. 2013 Jul 15;29(14):1813-4
pubmed: 23742983
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Nucleic Acids Res. 2014 Jan;42(Database issue):D109-13
pubmed: 24163250
Genome Res. 2014 Mar;24(3):365-76
pubmed: 24347612
Nucleic Acids Res. 2014 Jun;42(11):6876-84
pubmed: 24829451
Nat Commun. 2014 Aug 27;5:4726
pubmed: 25158696
Virology. 2015 Nov;485:363-70
pubmed: 26335850
Cancer Cell. 2015 Oct 12;28(4):515-528
pubmed: 26439496
Cell Rep. 2015 Oct 13;13(2):277-89
pubmed: 26440892
Cell Rep. 2015 Oct 13;13(2):267-76
pubmed: 26440895
Sci Rep. 2015 Oct 09;5:14941
pubmed: 26449202
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
Trends Genet. 2016 Mar;32(3):165-175
pubmed: 26803450
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Stem Cells Int. 2016;2016:7849890
pubmed: 26880988
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
PLoS Genet. 2016 Jul 22;12(7):e1006140
pubmed: 27448097
Nucleic Acids Res. 2017 Jan 4;45(D1):D750-D757
pubmed: 27587585
Cell Rep. 2016 Nov 15;17(8):2004-2014
pubmed: 27851964
J Biol Chem. 2017 Mar 10;292(10):4326-4335
pubmed: 28167531
Sci Data. 2017 Mar 14;4:170024
pubmed: 28291232
JCI Insight. 2017 Aug 3;2(15):null
pubmed: 28768910
Hum Genet. 2017 Sep;136(9):1265-1278
pubmed: 28913566
Mutat Res. 2017 Jul;773:1-13
pubmed: 28927521
Nature. 2017 Oct 11;550(7675):249-254
pubmed: 29022589
Curr Opin Genet Dev. 2018 Feb;48:51-56
pubmed: 29127844
Nucleic Acids Res. 2018 Feb 28;46(4):2045-2059
pubmed: 29267965
EBioMedicine. 2018 Jan;27:167-175
pubmed: 29273356
Cancer Cell. 2018 May 14;33(5):817-828.e7
pubmed: 29706454
Oncogene. 2018 Aug;37(35):4887-4900
pubmed: 29780166
Cell Physiol Biochem. 2018;47(6):2602-2612
pubmed: 29996118
Nat Commun. 2018 Sep 25;9(1):3919
pubmed: 30254248
Nature. 1993 Oct 14;365(6447):671-3
pubmed: 8413632
Sci Am. 1996 Sep;275(3):62-70
pubmed: 8701295